Sulfasalazine and pentoxifylline in psoriasis: A possible safe alternative

Journal of Dermatological Treatment

Volumn 22, Issue 1, 2011, Pages 31-37

  El Mofty, Medhat ^a   El Darouti, Mohamed ^a   Rasheed, Hoda ^a   Bassiouny, Dalia Ahmed ^a   Abdel Halim, Mona ^a   Zaki, Naglaa Sameh ^a   El Hanafy, Ghada ^a   El Hadidi, Heba ^a   Azzam, Omar ^a   El Ramly, Amany ^a   Fawzy, Marwa ^a  

^a Cairo University   (Egypt)

Author keywords

Combination therapy; Pentoxifylline; Psoriasis; Sulfasalazine; TNF antagonists

Indexed keywords

ANTIPSORIASIS AGENT; METHOTREXATE; PENTOXIFYLLINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; MALE; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PSORIASIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SULFASALAZINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650940407     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903460260     Document Type: Article

References (31)

1. Linden KG, Weinstein GD. Psoriasis: Current perspectives with an emphasis on treatment. Am JMed. 1999;107:595-605.
2. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50:416-430.
3. Lebwohl M. Psoriasis. In: Lebwohl M, Heymann WR, Berth-Jones J, Coulson I, editors. Treatment of skin diseases. Comprehensive therapeutic strategies. 1st ed. Mosby International; London 2002. p. 533-543.
4. Shanahan F, Niederlehner A, Carramanzana N, Anton P. Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology. 1990;20(3):217-224.
5. Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS. Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: A novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997;53(12):1901-1907.
6. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grünwald C, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology. 1994;83(2):262-267.
7. El-Darouti M, Marzouk S, Abdel Hay R, El Tawdy A, Fawzy M, Leheta T, et al. The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: A comparative study. Br J Dermatol. 2009;161(2):313-319. Epub 2009 Apr 10.
8. Gilhar A, Grossman N, Kahanovicz S, Reuveni H, Cohen S, Eitan A. Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis. In vitro and in vivo studies. Acta Derm Venereol. 1996;76(6):437-441.
9. Franklin JL, Rosenberg HH. Impaired folic acid absorption in inflammatory bowel disease: Effects of salicylazosulfapyridine (Azulfidine). Gastroenterology. 1973;64(4):517-525.
10. Halsted CH, Gandhi G, Tamura T. Sulfasalazine inhibits the absorption of folates in ulcerative colitis. N Engl J Med. 1981;305(25):1513-1517.
11. Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev. 2000;((3):CD000212.
12. Marguerie L, Flipo RM, Grardel B, Beaurain D, Duquesnoy B, Delcambre B. Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint Bone Spine. 2002;69(3):275-281. (Pubitemid 34654362)
13. Gupta AK, Ellis CN, Siegel MT, Voorhees JJ. Sulfasalazine: A potential psoriasis therapy? J Am Acad Dermatol. 1989;20 (5 Pt 1):797-800.
14. Gupta AK, Ellis CN, Siegel MT, Duell EA, Griffiths CE, Hamilton TA, et al. Sulfasalazine improves psoriasis. A double-blind analysis. ArchDermatol. 1990;126(4):487-493.
15. Omulecki A, Broniarczyk-Dyla G, Zak-Prelich M, Choczaj- Kukula A. Is pentoxifylline effective in the treatment of psoriasis? J Am Acad Dermatol. 1996;34(4):714-715.
16. Magela Magalhães G, Coelho da Silva Carneiro S, Peisino do Amaral K, de Freire Cássia F, Machado-Pinto J, Cuzzi T. Psoriasis and pentoxifylline: A clinical, histopathologic, and immunohistochemical evaluation. Skinmed. 2006;5(6):278-284.
17. Marks R, Barton S, Shuttelworth D, Finlay AY. Assessment of diseaseprogress inpsoriasis.ArchDermatol.1989;125:235-240.
18. Baumgartner TA, Strong CH. Conducting and reading research in health and human performances. 2nd ed. McGraw Hill; Colombus USA 1998.
19. Zargari O. Pentoxifylline: A drug with wide spectrum applications in dermatology. Dermatol Online J. 2008; 14(11):2.
20. Van Furth AM, Verhard-Seijmonsbergen EM. Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-alpha, IL-1 beta IL-10 by human leucocytes. Immunology. 1997;91:193-196.
21. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988;155:1230-1236.
22. Kano Y, Hirayama K, Orihara M, Shiohara T. Successful treatment of Schambergs disease with pentoxifylline. J Am Acad Dermatol. 1997;36:827-830.
23. Bruynzeel I, van der Raaij LM, Willemze R, Stoof TJ. Pentoxifylline inhibits human T-cell adhesion to dermal endothelial cells. Arch Dermatol Res. 1997;289(4):189-193.
24. Cohen KL, Lucibello FE, Chomiak M. Lack of effect of clonidine and pentoxifylline in short-term therapy of diabetic peripheral neuropathy. Diabetes Care. 1990;13:1074-1077.
25. Lee SS, Ang P, Tan SH. Clinical profile and treatment outcome of livedoid vasculitis: A case series. Ann Acad Med Singapore. 2003;32:835-839.
26. Bissonnette EY, Enciso JA, Befus AD. Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-alpha production by mast cells. J Immunol. 1996;156:218-223.
27. Bessler H, Gilgal R, Djaldetti M, Zahavi I. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol. 1986;40:747-754.
28. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: An in vivo study in patients with Crohns disease. Aliment Pharmacol Ther. 2002;16:79-85.
29. Raoul JM, Peterson MR, Peterson TC. A novel drug interaction between the quinolone antibiotic ciprofloxacin and a chiral metabolite of pentoxifylline. Biochem Pharmacol. 2007;74:639-646.
30. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of their quality. Br J Dermatol. 1999;141:185-191.
31. Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: Comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat. 2003;14:158-165.